Commercialization, License Deal

Aldeyra Therapeutics

21/12/2023 22:24

Dec 21 (Reuters) - Abbvie Inc  ABBV.N :
    * ALDEYRA THERAPEUTICS -  ABBVIE EXTENDED PERIOD DURING
WHICH IT
MAY EXERCISE OPTION TO ENTER INTO CO-DEVELOPMENT,
CO-COMMERCIALIZATION, LICENSE DEAL
    * ALDEYRA THERAPEUTICS INC - IF LICENSE AGREEMENT IS ENTERED
INTO,
OPTION EXTENSION FEE WILL BE CREDITED AGAINST UPFRONT CASH
PAYMENT PAYABLE BY ABBVIE
    * ALDEYRA THERAPEUTICS INC -  ABBVIE EXTENDED PERIOD FOR
OPTION TO
ENTER LICENSE AGREEMENT BY PAYING CO A NON-REFUNDABLE PAYMENT OF
$5 MILLION

Further company coverage:  ABBV.N 

 ((Reuters.Briefs@thomsonreuters.com;))